Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00146588 · ClinicalTrials.gov registry record · NA
Cytoxan, Epirubicin and Capecitabine in Women With Breast Cancer
A NA study of Breast Cancer and Stage II Breast Cancer, sponsored by Craig A. Bunnell, MD, MPH.
- Completed
- Registry status
- NA
- Development phase
- 55
- Enrollment target
- 2
- Study locations
NCT00146588: Completed NA study of Breast Cancer and Stage II Breast Cancer, sponsored by Craig A. Bunnell, MD, MPH.
NCT00146588 is a NA study of Breast Cancer and Stage II Breast Cancer that has completed, run by Craig A. Bunnell, MD, MPH. The registered enrollment target is 55 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00146588, a NA study of Breast Cancer and Stage II Breast Cancer, has completed, sponsored by Craig A. Bunnell, MD, MPH.
- COMPLETED
- Registry status
- NA
- Development phase
- 55 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to find out what effects (good and bad) a combination of cytoxan, epirubicin, and capecitabine have on women with Stage II/II/IIIA breast cancer.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Capecitabine
- DRUG Epirubicin
Study Locations (2)
Massachusetts
- Massachusetts General Hospital - Boston
- Dana-Farber Cancer Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2002-04 |
| Est. Completion | 2004-12 |
| Phase | NA |
What the finished NCT00146588 record still lists
NCT00146588 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower).
The record links to 4 conditions, with Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT00146588 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00146588 about?
NCT00146588 is a clinical study titled "Cytoxan, Epirubicin and Capecitabine in Women With Breast Cancer". The purpose of this study is to find out what effects (good and bad) a combination of cytoxan, epirubicin, and capecitabine have on women with Stage II/II/IIIA breast cancer.
What is the current status of trial NCT00146588?
This trial is currently completed. It is a NA study. The enrollment target is 55 participants. The study started on 2002-04. Estimated completion is 2004-12.
What conditions does trial NCT00146588 study?
This clinical trial studies the following conditions: Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage I Breast Cancer.
What interventions are being tested in trial NCT00146588?
The interventions under investigation include: Cyclophosphamide (DRUG), Capecitabine (DRUG), Epirubicin (DRUG).
Who is sponsoring clinical trial NCT00146588?
This trial is sponsored by Craig A. Bunnell, MD, MPH, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00146588 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00146588's enrollment target sits among peer trials
55 767th of 1224 higher than 452 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
-
Resistance and Aerobic Exercise for Prevention in Women With Dense Breasts (REP-D)
RECRUITING · NA
-
Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)
RECRUITING · NA
-
A Randomized Controlled Trial (RCT) to Determine the Efficacy of a Multidisciplinary CBT Based Pain Management Program for the Treatment of Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS) in Breast Cancer Survivors
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia